Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to transform oncology drug development, will present the growth plan for its wholly owned subsidiary Open-Medicine AI (OMAI) during a live webinar today at 12:30 p.m. Eastern. The 45-minute session, led by CEO Panna Sharma, will cover OMAI's market opportunity, customer feedback, platform capabilities, development roadmap, economics, benchmarks, potential partnerships and contribution to shareholder value.
OMAI is developing a multi-agentic AI platform for drug development. Its core capabilities and initial platform were developed within Lantern's clinical programs and areas of focus. Launched as withZeta.ai in April 2026 with an initial focus on rare cancers, the platform is expanding into additional diseases, therapy types and stages of drug development. The webinar will include a live demonstration followed by a question-and-answer session.
This announcement matters because it signals a significant step in the application of artificial intelligence to pharmaceutical research and development. By leveraging AI to streamline drug development, Lantern Pharma aims to reduce costs, accelerate timelines and improve precision in identifying patients most likely to benefit from therapies. The expansion of OMAI into new disease areas and therapy types could open up broader markets and attract partnerships, potentially driving value for shareholders and advancing treatment options for patients.
Lantern Pharma's proprietary RADR artificial intelligence and machine-learning platform integrates large-scale genomic and biological data to guide biomarker-driven clinical development. The company's pipeline includes LP-184 (zirdafulven), LP-300 and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For more details, the full press release is available at https://ibn.fm/SpEDF.
Investors and industry watchers can find the latest news and updates relating to LTRN in the company's newsroom at https://ibn.fm/LTRN. The webinar is expected to provide insights into how OMAI plans to capture market opportunities and deliver value, making it a key event for those following AI in drug development.
As a specialized communications platform focused on AI advancements, AINewsWire ("AINW") is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. AINW also provides editorial syndication to 5,000+ outlets and enhanced press release enhancement to ensure maximum impact, along with social media distribution and tailored corporate communications solutions.
For more information, visit www.AINewsWire.com. Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer.
